reparixin

inhibits CXCR1 to prevent polymorphonuclear cell recruitment

Also Known As:

(R)-2-(4-isobutylphenyl)propionylmethanesulfonamide; 2-(4-isobutylphenyl)propionylmethanesulfonamide; DF 1681Y; DF-1681Y; DF1681Y; reparixin lysine; reparixin lysine salt; repertaxin

Networked: 70 relevant articles (12 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - reparixin: 70
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - reparixin: 70

Experts

1.	Allegretti, Marcello: 11 articles (08/2022 - 08/2004)
2.	Ruffini, Pier Adelchi: 7 articles (11/2021 - 04/2015)
3.	Bertini, Riccardo: 7 articles (09/2007 - 08/2004)
4.	Brandolini, Laura: 4 articles (01/2022 - 12/2015)
5.	Goldstein, Lori J: 4 articles (11/2021 - 09/2017)
6.	McCanna, Susan: 4 articles (11/2021 - 09/2017)
7.	Colotta, Francesco: 4 articles (06/2005 - 08/2004)
8.	De Pizzol, Maria: 3 articles (08/2022 - 12/2015)
9.	Piemonti, Lorenzo: 3 articles (08/2022 - 04/2015)
10.	Butler, Beth: 3 articles (11/2021 - 01/2020)

Related Diseases

1.	Inflammation (Inflammations) 03/01/2007 - "Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. " 05/01/2022 - "Therefore, inhibition of IRI through the regulation of inflammation using a CXCL8 receptor inhibitor reparixin is an attractive target. " 01/01/2021 - "In addition, inhibition of the CXCL1/CXCR2 axis by repertaxin alleviates renal inflammation and pathological damage in the kidneys of db/db mice. " 01/01/2011 - "Prophylactic treatment with repertaxin had no effect on acute inflammation or liver injury. " 01/01/2007 - "We therefore tested the effects of reparixin on humoral and cellular parameters in LPS-induced acute systemic inflammation. "
2.	COVID-19 08/01/2022 - "In patients with severe COVID-19, reparixin led to an improvement in clinical outcomes when compared with the SOC. A larger phase 3 clinical study is needed to confirm these results. " 10/01/2023 - "Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study." 01/01/2023 - "Response to "Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia"." 01/01/2023 - "Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia." 08/01/2022 - "A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia."
3.	Acute Lung Injury 10/01/2008 - "Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice." 02/01/2019 - "The current study was designed to determine whether or not CXCR1/2 blockade with reparixin ameliorates acute lung injury (ALI) by affecting neuropeptides in a LPS-induced sepsis mouse model. " 02/03/2015 - "One aim of this study was to evaluate whether a low-dose of DEX in combination with the antioxidant N-acetyl cysteine (NAC) and if different treatments (Triptolide, Reparixin and Rolipram) administered 1h after Cl2-exposure could improve protection against acute lung injury in Cl2-exposed mice. "
4.	Neoplasms (Cancer) 04/01/2016 - "Repertaxin, a CXCR1/2 small-molecule inhibitor, has been shown to attenuate many of these tumor-associated processes. " 05/30/2017 - "Multiple anti-tumor effects of Reparixin on thyroid cancer." 04/01/2016 - "The improved effect of repertaxin and 5-FU was also observed in vivo, as xenograft models treated with both compounds exhibited significantly decreased tumor volume and increased apoptosis. " 11/25/2023 - "Moreover, repertaxin attenuated the protection of CAFs to cancer cells that were resistant to CD8+ T-cell cytotoxicity, and improved the antibody effects of anti-PD-L1 facilitating CD8+ T-cell cytotoxicity by targeting IL-8. " 07/01/2018 - "The present study aimed to demonstrate that treatment with the clinical grade CXCR1/2 antagonist, reparixin, or the newly discovered CXCR1/2 antagonist, SCH527123, may result in a reduction of the malignant features associated with this lethal cancer. "
5.	Breast Neoplasms (Breast Cancer) 08/01/2022 - "The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer. " 10/01/2020 - "A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer." 01/01/2020 - "Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer." 02/01/2010 - "CXCR1 blockade using either a CXCR1-specific blocking antibody or repertaxin, a small-molecule CXCR1 inhibitor, selectively depleted the CSC population in 2 human breast cancer cell lines in vitro. " 12/22/2015 - "Reparixin, a powerful CXCR1 inhibitor, was effective in reducing in vivo the tumour-initiating population in several NOD/SCID mice breast cancer models, showing that the selective targeting of CXCR1 and the combination of reparixin and docetaxel resulted in a concomitant reduction of the bulk tumour mass and CSC population. "

Related Drugs and Biologics

1.	Interleukin-8 (Interleukin 8)
2.	Rolipram
3.	Neuropeptides
4.	Fluorouracil (Carac)
5.	Cysteine (L-Cysteine)
6.	Antioxidants
7.	triptolide
8.	Chemokine Receptors
9.	Docetaxel (Taxotere)
10.	2'- ((4'- trifluoromethanesulfonyloxy)phenyl)- N- methanesulfonylpropionamide

Related Therapies and Procedures

1.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
2.	Therapeutics
3.	Islets of Langerhans Transplantation
4.	Drug Therapy (Chemotherapy)
5.	Chemoprevention